Strategy for measuring and managing stress and anxiety in stage 2 Type 1 Diabetes
Keywords:
stress, anxiety, type 1 diabetesAbstract
The identification of type 1 diabetes in its early stages through population-based screening programs has modified the traditional approach to the disease, incorporating attention to psychosocial needs from the presymptomatic stage.
Consensus documents recommend the systematic assessment of psychosocial well-being, family adjustment, risk understanding, and educational needs from early stages of type 1 diabetes (Haller et al., 2024; Phillip et al., 2024; Trifone et al., 2025; Hussain et al., 2026). While these recommendations do not establish specific psychometric instruments, the specialized literature supports the use of validated scales and strategies to assess anxiety, depression, diabetes-related distress, periodic risk perception assessment, quality of life, and family functioning. Communicating a positive autoantibody result can generate uncertainty, anxiety, depressive symptoms, emotional overload, and difficulties in understanding the risk, especially for caregivers. Therefore, incorporating psychological support from the time of screening is recommended to reduce stress (Haller et al., 2024; Phillip et al., 2024).
The systematic incorporation of these tools would allow the early detection of psychological vulnerability factors, guide individualized psychoeducational interventions, and strengthen family adaptation. Early-stage diagnosis can be experienced as threatening, uncontrollable, and unpredictable. In this context, the assessment of cognitive, emotional, and behavioral variables is an essential component of comprehensive follow-up in the early stages of type 1 diabetes and a priority for developing person- and family-centered care models (Phillip et al., 2024; Hussain et al., 2026). The integration of psychoeducational strategies and mental health assessment tools is an essential component for reducing the psychological impact of presymptomatic diabetes diagnosis through continuous interdisciplinary monitoring, thus promoting a healthier transition to symptomatic diabetes.
References
I. Haller MJ, Bell KJ, Besser REJ, et al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes. Horm Res Paediatr. 2024;97:529–545.
II. Phillip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024.
III. Hussain S, Tree T, Mathieu C, et al. An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementation. Diabetes Obes Metab. 2026;28:3535–3556.
IV. Trifone, L., Ferraro, M., Valdez, S., Frechtel, G., & Caratcoche, L. (2025). Recomendaciones en predicción de diabetes mellitus tipo 1: Detección, estadificación y estrategias para preservar la función de las células beta en niños, niñas y adolescentes con diabetes tipo 1. Revista de la Sociedad Argentina de Diabetes, 59(3), 176-192. https://doi.org/10.47196/diab.v59i3.1293
Downloads
Published
Issue
Section
License
Copyright (c) 2026 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.













